Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia

Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges. Recent studies have uncovered role...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Maharaj, Kamira, Powers, John J., Achille, Alex, Deng, Susan, Fonseca, Renee, Pabon-Saldana, Mibel, Quayle, Steven N., Jones, Simon S., Villagra, Alejandro, Sotomayor, Eduardo M., Sahakian, Eva, Pinilla-Ibarz, Javier
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2018
Konular:
Immunobiology and Immunotherapy
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234358/
https://ncbi.nlm.nih.gov/pubmed/30425065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018020065
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller